Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

E2F-8 Inhibitors

E2F-8 inhibitors belong to a distinctive chemical class that specifically targets the E2F-8 protein, a member of the E2F family of transcription factors. E2F proteins play a crucial role in regulating the cell cycle, influencing processes such as DNA synthesis and cell division. E2F-8, in particular, has been identified as a key modulator in controlling cell proliferation and differentiation. In normal cellular processes, E2F-8 acts as a transcriptional repressor, dampening the expression of genes involved in cell cycle progression. However, aberrant regulation of E2F-8 has been implicated in various pathological conditions, including cancer, where its overexpression is associated with uncontrolled cell proliferation and tumor progression.

E2F-8 inhibitors represents a significant advancement in the field of molecular pharmacology. These inhibitors are designed to selectively bind to E2F-8, disrupting its transcriptional regulatory activity. By doing so, E2F-8 inhibitors aim to restore the balance of cell cycle control and impede the unbridled proliferation of cells, particularly in contexts where E2F-8 dysregulation contributes to disease states. The chemical structure of E2F-8 inhibitors is meticulously crafted to achieve high specificity for the target protein while minimizing off-target effects. As research in this area progresses, a deeper understanding of the molecular interactions between E2F-8 and its inhibitors may pave the way for novel strategies aimed at modulating cellular processes associated with conditions driven by aberrant cell cycle regulation.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

CDK4/6 inhibitor that indirectly reduces E2F8 activity by preventing the phosphorylation of RB1, leading to cell cycle arrest.

Ribociclib

1211441-98-3sc-507367
10 mg
$450.00
(0)

Similar to Palbociclib, it inhibits CDK4/6, consequently blocking RB1 phosphorylation and reducing E2F8-mediated transcription.

Abemaciclib

1231929-97-7sc-507342
10 mg
$110.00
(0)

Another CDK4/6 inhibitor that indirectly hampers E2F8 by maintaining the RB1 protein in an active, hypophosphorylated state.

Flavopiridol

146426-40-6sc-202157
sc-202157A
5 mg
25 mg
$78.00
$259.00
41
(3)

Inhibits CDKs, including CDK4/6, and can indirectly decrease E2F8 activity by causing RB1-mediated cell cycle arrest.

Roscovitine

186692-46-6sc-24002
sc-24002A
1 mg
5 mg
$94.00
$265.00
42
(2)

A CDK inhibitor that can reduce E2F transcription factor activity, including E2F8, by stabilizing the RB1-E2F complex.

Dinaciclib

779353-01-4sc-364483
sc-364483A
5 mg
25 mg
$247.00
$888.00
1
(0)

Strongly inhibits multiple CDKs and may indirectly limit E2F8 activity via RB1 interaction.

Olomoucine

101622-51-9sc-3509
sc-3509A
5 mg
25 mg
$72.00
$274.00
12
(1)

A purine derivative that inhibits CDKs and could decrease E2F8 activity by affecting RB1 phosphorylation.

PHA-848125

802539-81-7sc-364581
sc-364581A
5 mg
10 mg
$304.00
$555.00
(0)

Targets multiple CDKs, potentially affecting E2F8 activity through RB1-E2F regulatory control.

AT7519

844442-38-2sc-364416
sc-364416A
sc-364416B
sc-364416C
5 mg
10 mg
100 mg
1 g
$291.00
$341.00
$1046.00
$3126.00
1
(0)

Inhibits various CDKs, possibly leading to reduced E2F8 activity by enhancing RB1's inhibitory effect on E2F-regulated transcription.